banner

SupporT | Products |  My Account | Home  

 

In This Issue:

December 11, 2006 — Issue No. 66
 
 

New Study: Physicians Believe Epocrates
References Improve Patient Safety

In the largest study of its kind, researchers at Brigham and Women's Hospital and Harvard Medical School examined more than 1,500 physicians' usage of Epocrates mobile products. The recently published study found that:

  • Over 60% of participants reported preventing 3 or more adverse drug events in the prior month with Epocrates.

  • On average, physicians reported using the Epocrates drug reference more than 5 times per day.

  • Nearly 40% reported using Epocrates products during more than half of patient encounters.

  • Physicians who used the clinical references more frequently also reported more frequent benefits in improved care.

The study was published in the Journal of the American Medical Informatics Association, 2006;13:619-626.

Read the Study »

Epocrates ID Guide Updated

Epocrates ID GuideThe Epocrates Infectious Disease team has updated the Bone/Joint and GI sections of Epocrates ID. 

Highlights of ID changes:

Bone/Joint — reviewed and revised treatments for osteomyelitis and septic arthritis in pediatrics and adults
GI — reviewed and revised treatments for chronic hepatitis B and acute gastroenteritis in adults

The Epocrates ID treatment guide is available in Epocrates Rx Pro® and Epocrates® Essentials premium products.
Current subscribers: simply AutoUpdate (sync) to receive these updates for free.

Free Dosing Tool

Exubera® is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. The new Exubera Dosing tool for Palm OS® devices contains an initial dosage calculator for prescribing Exubera, approximate equivalent regular insulin SC dose in IU, and information on how Exubera is supplied.

Site License Trial

We would like to offer your organization a complimentary 30-day trial of a site license for the Epocrates® Online Premium drug and formulary reference. Contact us today to learn how you can take advantage of this great offer!

Request a Trial »

 

 

Updates At A Glance

To receive these updates on your mobile device, simply AutoUpdate!

Clinical Updates

New monographs include:

  • FluLaval (influenza vaccine) — vaccine for immunization against influenza virus subtypes A and type B in adults 18 years and older
  • Januvia (sitagliptin) — new FDA-approved oral tablet for the treatment of type 2 diabetes mellitus in the adult population

See All Clinical Updates »


MobileCME®

Complete your 2006 CME requirement with Epocrates MobileCME!

With the holidays quickly approaching, maximize your time with family and patients by earning CME credits on your handheld device.

Open MobileCME in your black bag tab today for more than 100 CME opportunities, including:

  • Improving Contraceptive Outcomes
  • Anti-EGF Therapy in Colorectal Cancer Management
  • Young Adult Stroke Case Study
  • Diabetes'Impact on BP Medication Selection

Don't have MobileCME?

Get MobileCME - Free! »

 

Quick Poll

What makes this holiday season most special for you?

  • Decorations
  • Gifts
  • Good food
  • Holiday movies
  • Time with friends and family
  • Traditions
  • Winter vacation
  • Snow

Thank you for supporting Epocrates in 2006. Happy Holidays from the Epocrates Team!

Last month we asked you if your senior patients were planning to make a change to their Medicare Part D plans on November 15th.
The majority, 54%, said yes. 46% said no.

Epocrates, Inc., 1100 Park Place Suite 300, San Mateo, CA 94403 | www.epocrates.com